KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Operating Income: 2016-2024

Historic Operating Income for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.9 billion.

  • Moderna's Operating Income fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
  • As of FY2024, Moderna's Operating Income stood at -$3.9 billion, which was up 6.94% from -$4.2 billion recorded in FY2023.
  • In the past 5 years, Moderna's Operating Income ranged from a high of $13.3 billion in FY2021 and a low of -$4.2 billion during FY2023.
  • Over the past 3 years, Moderna's median Operating Income value was -$3.9 billion (recorded in 2024), while the average stood at $412.0 million.
  • Its Operating Income has fluctuated over the past 5 years, first surged by 1,842.60% in 2021, then tumbled by 145.00% in 2023.
  • Over the past 5 years, Moderna's Operating Income (Yearly) stood at -$763.0 million in 2020, then soared by 1,842.60% to $13.3 billion in 2021, then declined by 29.15% to $9.4 billion in 2022, then slumped by 145.00% to -$4.2 billion in 2023, then increased by 6.94% to -$3.9 billion in 2024.